Morgan Stanley lowered shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from an overweight rating to an equal weight rating in a research report sent to investors on Friday. They currently have $36.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $38.00.
A number of other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. cut Alnylam Pharmaceuticals from an overweight rating to a neutral rating and cut their price objective for the stock from $83.00 to $51.00 in a report on Thursday, October 6th. Jefferies Group dropped their target price on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a buy rating for the company in a report on Thursday, October 6th. Credit Suisse Group AG set a $145.00 target price on Alnylam Pharmaceuticals and gave the company a buy rating in a report on Friday, September 30th. FBR & Co restated an outperform rating and set a $180.00 target price on shares of Alnylam Pharmaceuticals in a report on Sunday, July 17th. Finally, Zacks Investment Research cut Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Monday, July 25th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $79.50.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 35.76 on Friday. The company’s market capitalization is $3.07 billion. Alnylam Pharmaceuticals has a one year low of $33.16 and a one year high of $110.75. The firm has a 50-day moving average price of $67.30 and a 200-day moving average price of $65.51.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same period in the prior year, the business earned ($0.85) EPS. The company’s revenue for the quarter was up .2% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In other news, CEO John Maraganore sold 30,151 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.00% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth $128,000. Janney Montgomery Scott LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth $223,000. Seven Eight Capital LLC raised its position in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the period. Meeder Asset Management Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter worth $175,000. Finally, BlueMountain Capital Management LLC raised its position in Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares during the period. 85.96% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Company Profile